Ahmed O Elzoghby
Overview
Explore the profile of Ahmed O Elzoghby including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
80
Citations
1542
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hefnawy A, Abdelhamid A, Abdelaziz M, Elzoghby A, Khalil I
J Pharm Sci
. 2024 Aug;
113(11):3145-3172.
PMID: 39151795
Liver cancer is one of the aggressive primary tumors as evident by high rate of incidence and mortality. Conventional treatments (e.g. chemotherapy) suffer from various drawbacks including wide drug distribution,...
2.
Elzoghby A, Samir O, Emam H, Soliman A, Abdelgalil R, Elmorshedy Y, et al.
Acta Pharm Sin B
. 2024 Jun;
14(6):2475-2504.
PMID: 38828160
Resistance to cancer immunotherapy is mainly attributed to poor tumor immunogenicity as well as the immunosuppressive tumor microenvironment (TME) leading to failure of immune response. Numerous therapeutic strategies including chemotherapy,...
3.
Freag M, Mohammed M, Kulkarni A, Emam H, Maremanda K, Elzoghby A
Sci Adv
. 2024 Feb;
10(9):eadk3074.
PMID: 38416824
Cancer cells program fibroblasts into cancer associated fibroblasts (CAFs) in a two-step manner. First, cancer cells secrete exosomes to program quiescent fibroblasts into activated CAFs. Second, cancer cells maintain the...
4.
Dogheim G, El Feel N, Abd El-Maksod E, Amer S, El-Gizawy S, Abd Elhamid A, et al.
Drug Discov Today
. 2024 Jan;
29(3):103905.
PMID: 38295898
The potential of cancer immunotherapy is hampered by the poor immunogenicity of cancer cells. Strategies to enhance tumor immunogenicity are imperative to enhance T cell-mediated anti-tumor immunity. Although conventional therapeutics...
5.
Elmorshedy Y, Teleb M, Sallam M, Elkhodairy K, Bahey-El-Din M, Ghareeb D, et al.
Biomacromolecules
. 2023 Apr;
24(5):2149-2163.
PMID: 37039769
Despite current progress in the development of targeted therapies for cancer treatment, there is a lack in convenient therapeutics for colorectal cancer (CRC). Lactoferrin nanoparticles (Lf NPs) are a promising...
6.
Abdelgalil R, Khattab S, Ebrahim S, Elkhodairy K, Teleb M, Bekhit A, et al.
ACS Omega
. 2023 Feb;
8(6):5655-5671.
PMID: 36816638
Despite extensive progress in the field of cancer nanotheranostics, clinical development of biocompatible theranostic nanomedicine remains a formidable challenge. Herein, we engineered biocompatible silk-sericin-tagged inorganic nanohybrids for efficient treatment and...
7.
Nasser T, Adel R, Badr A, Teleb M, Bekhit A, Elkhodairy K, et al.
ACS Omega
. 2023 Feb;
8(5):4491-4507.
PMID: 36777563
Cancer is among the main causes of mortality all over the world. The delayed diagnosis is directly related to the decrease in survival rate. The use of immunotherapy has dramatically...
8.
Abdelgalil R, Elmorshedy Y, Elkhodairy K, Teleb M, Bekhit A, Khattab S, et al.
Nanomedicine (Lond)
. 2023 Jan;
17(22):1721-1745.
PMID: 36621872
Colorectal cancer (CRC) is one of the most devastating diseases worldwide. Immunotherapeutic agents for CRC treatment have shown limited efficacy due to the immunosuppressive tumor microenvironment (TME). In this context,...
9.
Elzoghby A, Ferrone C, Ferrone S, Nasr M
Drug Discov Today
. 2022 Nov;
28(1):103434.
PMID: 36368630
Pancreatic cancer (PC) is a highly aggressive malignant type of cancer. Although immunotherapy has been successfully used for treatment of many cancer types, many challenges limit its success in PC....
10.
Salah M, Sallam M, Abdelmoneem M, Teleb M, Elkhodairy K, Bekhit A, et al.
Pharmaceutics
. 2022 Nov;
14(11).
PMID: 36365222
While breast cancer remains a global health concern, the elaboration of rationally designed drug combinations coupled with advanced biocompatible delivery systems offers new promising treatment venues. Herein, we repurposed rosuvastatin...